In order to determine whether Orai1 inhibition with CM5480 monotherapy could be considered as a new therapeutic avenue to reduce the development of MCT-PAH, we administered CM5480 in vivo from week 2 to week 3 to control and MCT-PAH male and female rats when PAH was established (Figure 1A). Here, ORAI1 is linked to pulmonary arterial hypertension.